Mark R. Underwood
Infectious Diseases MDD
3.2104 GlaxoSmithKline
5 Moore Dr.
Research Triangle Park
Name/email consistency: high
- Dolutegravir (S/GSK1349572) Exhibits Significantly Slower Dissociation than Raltegravir and Elvitegravir from Wild-Type and Integrase Inhibitor-Resistant HIV-1 Integrase-DNA Complexes. Hightower, K.E., Wang, R., Deanda, F., Johns, B.A., Weaver, K., Shen, Y., Tomberlin, G.H., Carter, H.L., Broderick, T., Sigethy, S., Seki, T., Kobayashi, M., Underwood, M.R. Antimicrob. Agents Chemother. (2011)
- Sensitivity of phenotypic susceptibility analyses for nonthymidine nucleoside analogues conferred by K65R or M184V in mixtures with wild-type HIV-1. Underwood, M.R., Ross, L.L., Irlbeck, D.M., Gerondelis, P., Rouse, E., St Clair, M.H., Trinh, L., Parkin, N., Lanier, E.R. J. Infect. Dis. (2009)
- Mechanism of action of the ribopyranoside benzimidazole GW275175X against human cytomegalovirus. Underwood, M.R., Ferris, R.G., Selleseth, D.W., Davis, M.G., Drach, J.C., Townsend, L.B., Biron, K.K., Boyd, F.L. Antimicrob. Agents Chemother. (2004)